Spinal cord compression

Enhancing Chiropractic Practices: A Comprehensive Guide to Essential Equipment

Retrieved on: 
Thursday, January 11, 2024
Table, Patient, Tendon, Spinal cord compression, Health, Multimedia, TENS, Ligament, Pain, Inflammation, Cryotherapy

DALLAS, Jan. 11, 2024 /PRNewswire-PRWeb/ -- In the realm of chiropractic care, success is not solely dependent on effective treatment and superior patient service; it also hinges on the strategic investment in cutting-edge equipment. As practitioners strive to elevate their offices and meet the evolving demands of the profession, the inclusion of key items on the chiropractic equipment list becomes paramount.

Key Points: 
  • This comprehensive article highlights the crucial role of cutting-edge equipment in the success of chiropractic practices.
  • Notably, the article directs practitioners to ChiroEquip.com, a premier online destination offering a diverse array of essential tools from renowned industry brands, including Pivotal Health Solutions and Elite Chiropractic Tables.
  • As practitioners strive to elevate their offices and meet the evolving demands of the profession, the inclusion of key items on the chiropractic equipment list becomes paramount.
  • For chiropractors seeking a comprehensive selection of equipment from renowned industry brands such as Pivotal Health Solutions and Elite Chiropractic Tables, www.ChiroEquip.com emerges as a premier online destination.

Zetagen Announces Publication in Pain Management of Early Data Using ZetaMet™ as a Potential Treatment for Bone Metastases

Retrieved on: 
Tuesday, October 10, 2023
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Pain, Calcium, Cancer, Patent, Disease, Food, Doctor of Philosophy, Cell, MD, Risk, Breast cancer, Osteolysis, National Cancer Institute, Spinal cord compression, Prostate, Pain management, Fracture, FDA, Therapy, SRE, NCI, Patient, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Blood, Series A round, Quality of life, NIH, Pharmaceutical industry, Medical imaging, Breast

Zetagen Therapeutics, a private, clinical-stage, biopharmaceutical company focused on driving breakthrough innovation in the treatment of metastatic cancers to bone and soft tissue organs as well as osteologic interventions, today announced publication of early, human clinical data in the peer-reviewed journal Pain Management on ZetaMet™ for the treatment bone metastases.

Key Points: 
  • Zetagen Therapeutics, a private, clinical-stage, biopharmaceutical company focused on driving breakthrough innovation in the treatment of metastatic cancers to bone and soft tissue organs as well as osteologic interventions, today announced publication of early, human clinical data in the peer-reviewed journal Pain Management on ZetaMet™ for the treatment bone metastases.
  • To view the publication via open access, go to: https://www.futuremedicine.com/doi/10.2217/pmt-2023-0069
    ZetaMet™ is a synthetic, small-molecule, inductive biologic technology being developed to target and resolve metastatic bone lesions while inhibiting future tumor growth and regenerating bone.
  • The small molecule has been approved by the U.S. Food and Drug Administration (FDA) since 1971.
  • Zetagen is focused on the more than 620,000 people in the United States, and more globally, living with metastatic cancers.

Medcura Receives Breakthrough Device Designation for its LifeGel™ Absorbable Surgical Hemostat

Retrieved on: 
Thursday, January 12, 2023
Swelling, Spinal cord compression, Regulation of tobacco by the U.S. Food and Drug Administration, Bleeding, FDA, Partnership, Food, Paralysis, Thrombin, Breakthrough, Spinal canal, Birth control, Pharmaceutical industry

COLLEGE PARK, Md., Jan. 12, 2023 /PRNewswire/ -- Medcura, Inc., a medical device company dedicated to transformatively improving the management of surgical bleeding, announces that the U.S. Food and Drug Administration (FDA) has granted the coveted Breakthrough Device Designation for its LifeGel™ Absorbable Surgical Hemostat.

Key Points: 
  • COLLEGE PARK, Md., Jan. 12, 2023 /PRNewswire/ -- Medcura, Inc., a medical device company dedicated to transformatively improving the management of surgical bleeding, announces that the U.S. Food and Drug Administration (FDA) has granted the coveted Breakthrough Device Designation for its LifeGel™ Absorbable Surgical Hemostat.
  • Due to its no-swell properties, LifeGel can be used in surgical procedures where swelling cannot be tolerated.
  • Breakthrough designation provides several important benefits, including quicker and more collaborative review of future regulatory submissions with greater opportunity to interact with FDA experts throughout the review process.
  • "This designation provides for a more collaborative partnership with the FDA which should expedite patient access to LifeGel as a game-changing new solution to surgical bleeding management."

Bristol Myers Squibb Announces Positive Topline Results of Phase 3 COMMANDS Trial

Retrieved on: 
Monday, October 31, 2022
Biotechnology, Pharmaceutical, Health, Clinical Trials, People, Hepatomegaly, Beta thalassemia, Safety, Hypertension, Myelodysplastic syndrome, Deep vein thrombosis, DBP, History, MDS, Splenomegaly, SBP, EMH, Patient, The Bristol-Myers Squibb Children's Hospital, BMY, RBC, NYSE, Risk, Stroke, ESA, Spinal cord compression, Adult, Clinical trial, Anemia, Acquisition, Iron overload, Embolism, HB, Lymphatic system, Merck, Portal vein thrombosis, Bristol Myers Squibb, Microdeletion syndrome, Incidence, TEE, Splenectomy, Thrombosis, Hormone replacement therapy, Pharmaceutical industry, Blood product

We are pleased with the positive results of the COMMANDS study and look forward to presenting these important data.

Key Points: 
  • We are pleased with the positive results of the COMMANDS study and look forward to presenting these important data.
  • Bristol Myers Squibb will complete a full evaluation of the COMMANDS data and work with investigators to present detailed results at an upcoming medical meeting, as well as discuss these results with health authorities.
  • Bristol Myers Squibb thanks the patients and investigators who are participating in the COMMANDS clinical trial.
  • For more information about Bristol Myers Squibb, visit us at BMS.com or follow us on LinkedIn , Twitter , YouTube , Facebook and Instagram .

Drs. Todd H. Lanman and Jason M. Cuellar Become First Surgeons in the U.S. to Perform 3-Level ADR With Prodisc® C Vivo

Retrieved on: 
Tuesday, October 18, 2022
CA, Vivo, Spinal cord compression, Cedars-Sinai Medical Center, Anatomy, Neck, Walking, ADR, Institute, Spine, MD, DRS, National Center for Spinal Disorders, GLOBE, FDA, Surgeon, Ronald Reagan UCLA Medical Center, Medical device

Todd Lanman and Jason Cuellarare again breaking new ground in their pioneering efforts in multi-level artificial disc replacement.

Key Points: 
  • Todd Lanman and Jason Cuellarare again breaking new ground in their pioneering efforts in multi-level artificial disc replacement.
  • Lanman and Cuellarbecame the first surgeons in the United States to implant prodisc C Vivo at three levels of the cervical spine.
  • The fourth implanted disc was the original prodisc C.
    The patient is an extremely active 76-year-old woman who enjoys various physical activities.
  • Todd H. Lanman, MD, and Jason M. Cuellar, M.D., Ph.D., are dedicated to spinal motion preservation surgery in the cervical and lumbar spines.

Accord BioPharma Partners with StoryMD to Deliver Advanced Prostate Cancer Educational Content to Clinicians and Patients

Retrieved on: 
Tuesday, September 20, 2022
Intas Biopharmaceuticals, Spinal cord compression, Electrolyte, Time, Extremities, Efficiency, Risk, Convulsion, Food, Association, Knowledge, Hypersensitivity, Hyperglycemia, Partnership, Gonadotropin-releasing hormone, NDA, Urinary tract obstruction, Stroke, Hypertension, QT, Critical care, Patient, Pregnancy, Severe cutaneous adverse reactions, Lists of diseases, Regulation of tobacco by the U.S. Food and Drug Administration, Accord, Physician, CEO, Leuprorelin, Technology, Paralysis, Pain, Biology, Serum, Cardiovascular disease, Drug development, Caregiver, New Drug Application, Anaphylaxis, Testosterone, Myocardial infarction, Prostate cancer, Medicine, Awareness, Man, Fatigue, Multimedia, Communication, Education, Disease, Cancer, Medical imaging, Pharmaceutical industry, Vaccine

Accord BioPharma has signed on as StoryMD's very first corporate partner, to support StoryMD's advanced prostate cancer content , allowing Accord BioPharma to provide a comprehensive, user-friendly tool to help patients and their caregivers navigate advanced prostate cancer, just in time for prostate cancer awareness month thisSeptember.

Key Points: 
  • Accord BioPharma has signed on as StoryMD's very first corporate partner, to support StoryMD's advanced prostate cancer content , allowing Accord BioPharma to provide a comprehensive, user-friendly tool to help patients and their caregivers navigate advanced prostate cancer, just in time for prostate cancer awareness month thisSeptember.
  • "StoryMD exemplifies that mission by providing clinicians with clear, easy-to-understand visuals, videos, and health information that help their patients understand their disease journey.
  • Partnering with StoryMD on their advanced prostate cancer content felt like a natural fit given our recent drug launch."
  • In March of this year, Accord BioPharma announced the U.S. launch of CAMCEVI (leuprolide) 42mg injection emulsion for the treatment of advanced prostate cancer in adults.

Accord BioPharma and EVERSANA Announce Partnership to Support the Launch of CAMCEVI® for the Treatment of Advanced Prostate Cancer in Adults in the U.S.

Retrieved on: 
Wednesday, June 29, 2022
Hyperglycemia, Critical care, Science, Patient, LinkedIn, CEO, Convulsion, Leuprorelin, New Drug Application, Biology, Adoption, Anaphylaxis, Man, Paralysis, Stroke, Lists of diseases, Industry, Disease, QT, Hypersensitivity, Pain, Association, Testosterone, Risk, Food, Partnership, Pharmacovigilance, Serum, Spinal cord compression, Intas Biopharmaceuticals, Organization, Fatigue, Cardiovascular disease, Myocardial infarction, Regulation of tobacco by the U.S. Food and Drug Administration, Electrolyte, Prostate cancer, Accord, Solution, Hypertension, Medicine, Gonadotropin-releasing hormone, Time, Drug development, Twitter, Urinary tract obstruction, Pregnancy, Extremities, NDA, Pharmaceutical industry

Leveraging the power of the company's integrated solutions, EVERSANA will provide multiple services to Accord BioPharma for CAMCEVI, including field deployment solutions, training, and the company's comprehensive data and analytics platform.

Key Points: 
  • Leveraging the power of the company's integrated solutions, EVERSANA will provide multiple services to Accord BioPharma for CAMCEVI, including field deployment solutions, training, and the company's comprehensive data and analytics platform.
  • Through this strategic partnership with EVERSANA for the launch of CAMCEVI, we are excited to sharpen Accord BioPharma's focus on specialty pharmaceuticals.
  • This will help us enablebetter access to therapy for advanced prostate cancer patients across the U.S.," said Binish Chudgar, Managing Director - Accord Healthcare and Accord BioPharma.
  • "It's why we built EVERSANA, to support the needs of clients like Accord BioPharma and help bring innovative drugs like CAMCEVI to market."

Tolmar Establishes Tolmar Canada to Sell, Market and Distribute ELIGARD® in Canada

Retrieved on: 
Friday, October 8, 2021
Man, Pain, Fatigue, Testosterone, History, Myalgia, Risk, Hypersensitivity, Gynecomastia, Dizziness, Convulsion, Food, Prostate cancer, Bone density, Pituitary apoplexy, Gonadotropin-releasing hormone, Hyperglycemia, Bruise, Marketing, Anaphylaxis, Fertility, Erythema, Peripheral neuropathy, Literature, FDA, Regulation of tobacco by the U.S. Food and Drug Administration, Serum, IL, Bone pain, Stroke, Weakness, Hematuria, CEO, Myocardial infarction, Spinal cord compression, Testicular atrophy, Patient, Cardiovascular disease, QT, Pharmaceutical industry

BUFFALO GROVE, Ill., Oct. 8, 2021 /PRNewswire/ -- Tolmar, a specialty pharmaceutical company, today announced that, effective January 1, 2022, the company will hold exclusive distribution rights to ELIGARD® (leuprolide acetate for injectable suspension) in Canada. ELIGARD® is a prescription medication for the palliative treatment of advanced prostate cancer.

Key Points: 
  • With the establishment of Tolmar Pharmaceuticals Canada, Tolmar will resume the rights to ELIGARD in the Canadian market.
  • Tolmar will exclusively market, sell, and distribute ELIGARD in Canada after those respective dates.
  • "We are excited to regain the sales and marketing rights for ELIGARDin Canada," said Anil D'souza, CEO of Tolmar Pharmaceuticals.
  • The establishment of Tolmar Pharmaceuticals Canada will allow Tolmar to continue to advance ELIGARDinto the future."

Worldwide Multiple Myeloma Drugs Industry to 2026 - Featuring Amgen, Daiichi Sankyo and Pfizer Among Others - ResearchAndMarkets.com

Retrieved on: 
Wednesday, August 25, 2021
Health, Pharmaceutical, Melphalan, CAGR, Lymphatic system, Multiple myeloma, Transplant, Nanomedicine, Therapy, Lists of diseases, Immune system, Doxorubicin, B cell, Efficiency, Research, Dexamethasone, Disease, Prevalence, R, Alkylation, Anemia, Hypercalcaemia, Bone fracture, Platelet transfusion, Vincristine, Bortezomib, MicroRNA, Thalidomide, Spinal cord compression, Bone marrow, Prednisone, Pharmaceutical industry

The "Multiple Myeloma Drugs Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2021-2026" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Multiple Myeloma Drugs Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2021-2026" report has been added to ResearchAndMarkets.com's offering.
  • Multiple myeloma, or Kahler's disease, refers to a form of blood cancer that primarily affects the plasma cells.
  • Some of the most common types of multiple myeloma drugs include chemotherapeutic agents, corticosteroids and immunomodulatory agents.
  • Looking forward, the publisher expects the global multiple myeloma drugs market to grow at a CAGR of around 10% during the forecast period (2021-2026).

Navega Therapeutics expands its Scientific Advisory Board with the addition of pain expert, Dr. Stephen Waxman.

Retrieved on: 
Tuesday, August 24, 2021
Genome, Human, NAV, Biophysics, Ion, Pain, Erythromelalgia, Gene, Peripheral neuropathy, Antibody, Molecular biology, CSO, Stanford University, MIT, Science, Harvard University, Research, DNA, RNA, Narcotic, Disease, Doctor of Philosophy, Therapy, Inherit, SAB, Risk, Multimedia, United States Air Force Scientific Advisory Board, IND, Paroxysmal extreme pain disorder, Chronic pain, Book, Patient, SAN, CEO, Spinal cord compression, Opioid overdose, Pharmaceutical industry, Poultry, Vaccine, Generic drug

One and a half billion people worldwide suffer from chronic pain, with more than 100 million in the US alone.

Key Points: 
  • One and a half billion people worldwide suffer from chronic pain, with more than 100 million in the US alone.
  • Navega Therapeutics is pursuing a radically different approach based on DNA targeting to treat chronic pain and tackle the opioid epidemic via epigenetic regulation of key genes.
  • About Navega Therapeutics Inc. | Navega is a preclinical stage company developing epigenetic-regulation gene therapies to tackle common disease.
  • The same pharmaceutical product will be utilized to reduce chronic pain in other pain disorders.